Cagrilintide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Cagrilintide itself has no standalone FDA approval. As a component of CagriSema, an NDA was filed with the FDA in December 2025; a decision is anticipated approximately October 2026 under the standard 10-month review clock. Supply and use outside of registered clinical trials is not authorised.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Cagrilintide

Origin

Synthetic acylated analogue of human amylin (islet amyloid polypeptide, IAPP), engineered by Novo Nordisk with C20 fatty-acid conjugation via a linker to extend half-life to approximately seven days; CAS 1415456-99-3.

Registry IDs

PubChem CID

171397054

CAS

1415456-99-3

InChIKey

LDERDVMBIYGIOI-IZVMHKDJSA-N

Molecular formula

C194H312N54O59S2

Molar mass

4409 g/mol

Monoisotopic

4406.2515111 Da

InChIKey

LDERDVMBIYGIOI-IZVMHKDJSA-N

Appearance

White to off-white lyophilised powder (typical for acylated peptides of this molecular weight)

Solubility

Soluble in aqueous buffers at physiological pH; fatty-acid conjugation requires …

Sequence not available in current seed.

Stability: Extended solution stability conferred by the C20 fatty-acid-linker conjugation; degradation pathways include methionine oxidation and deamidation typical of amy

Vial sizes

null mg

Purity grades

research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Cagrilintide binds as a non-selective agonist at amylin receptors AMY1, AMY2, and AMY3 — heterodimeric complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3, respectively
• Receptor engagement activates cAMP-dependent signalling cascades in the brainstem area postrema, suppressing appetite and reducing postprandial glucagon secretion
• The compound also slows gastric emptying, contributing to reduced caloric intake, and displays binding kinetics at the CTR that differ from those of salmon calcitonin despite a broadly similar in-vitro pharmacological profile
• The long-chain fatty-acid conjugation that confers the extended half-life does not alter the amylin-like binding mode at the receptor but induces distinct conformational dynamics relative to native amylin

Pharmacokinetics (ADME)

Half-life

~7.3 days (~180 hours); supports once-weekly subcutaneous dosing

Clearance

Not publicly characterised in detail; presumed renal/proteolytic as for other acylated peptides

PK–PD note: Single-compartment PK with subcutaneous bioavailability consistent with acylated GLP-1-class peptides; steady-state reached after ~4–5 weeks of weekly dosing based on phase 1b data (Lancet 2021, PMID …

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436–444. (PROSPERO CRD42023460291; 3 RCTs, n=430) — Anchoring systematic review/meta-analysis; analyzed 3 RCTs involving 430 individuals
• Ahmed et al. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab. — Systematic review/meta-analysis searching MEDLINE, Embase, Scopus, Cochrane, ClinicalTrials.gov
• CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of RCTs with GRADE Assessment. — Systematic review/meta-analysis with GRADE assessment; searched MEDLINE, Web of Science, Scopus, Cochrane through July 2025

5 registered trials — 1 currently recruiting.

Phase 2
NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

ACTIVE_NOT_RECRUITING

Phase 1
NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

COMPLETED

Phase 1
NCT07605052
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

NOT_YET_RECRUITING

Phase 1
NCT07607587
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

NOT_YET_RECRUITING

Phase 1
NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

RECRUITING

Summary (literature)

The most frequently reported adverse effects across phase 1b–3 trials are gastrointestinal: nausea, vomiting, diarrhoea, and constipation — consistent with amylin-class pharmacology and additive with co-administered semaglutide. In REDEFINE 1, gastrointestinal adverse events were…

WADA status

Not specifically listed by name on the 2026 WADA Prohibited List. However, because cagrilintide is an amylin analogue (peptide hormone), it may fall within the …

Dominant research route: SC

Once-weekly subcutaneous self-injection studied in adults with overweight/obesity (Phase 2 dose-finding, 706 participants, doses 0.3–4.5 mg) and in healthy participants (thorough QT study, 105 participants, dose escalated to 4.5 mg); also the route in Phase 3 REDEFINE/CagriSema trials

Bioavailability: Long-acting amylin analogue with N-terminally linked C20 fatty acid (albumin-binding) conferring prolonged in vivo presence and an approximately 7–7.3 day half-life, enabling once-weekly SC dosing; SC is the only route administered in clinical trials to date

All reported human RCTs (Phase 2 Lancet 2021; thorough QT Diabetes Obes Metab 2024; Phase 3 REDEFINE) administer cagrilintide as a once-weekly subcutaneous injection. No intramuscular, intravenous, intraperitoneal, intranasal, topical, or oral human route has been reported in the retrieved literature.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $9.80 · median $10.20 · p75 $17.00 · 6 researched vendors

Legit, COA-backed band: $9.80–$20.40/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$33

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-reported COAs for gray-market cagrilintide lyophilized powder commonly claim ≥98–99.6% HPLC purity (e.g., NovoProLabs 99.39%; Panda Peptides 99.63% HPLC). These are vendor self-reported values, not independent third-party confirmations retrieved here.

Independent labs cited for this compound

No FDA drug recall entries specific to cagrilintide were found in the FDA Drug Recalls database or Enforcement Reports reviewed; cagrilintide is not an FDA-approved drug and is not permitted in compounding, so no approved-product recall pathway applies. None found.

Buyer red-flag checklist

• Cagrilintide is not FDA-approved and, per FDA, 'cannot be used in compounding under federal law' (not a component of any FDA-approved drug).
• Multiple FDA Warning Letters (Prime Sciences 2026; Darmerica 2025) cite cagrilintide sold/distributed as unapproved/misbranded/adulterated injectable drugs.
• Gray-market vendors market cagrilintide with disease-treatment and weight-loss claims (e.g., '25% weight loss in 40.4% of patients') despite 'research purposes only' labeling — flagged by FDA as evidence of intended human drug use.
• Vendor-reported purity (≥98–99.6% HPLC) is self-declared; no retrieved independent third-party aggregate confirms identity/potency for gray-market cagrilintide.
• Cagrilintide API supply chains overlap with the GLP-1 API import-alert (66-80) enforcement environment where 21% of evaluated foreign API sites were CGMP-noncompliant.
• Darmerica warning letter documented inadequate supplier qualification and falsified vendor-survey responses for GLP-1/cagrilintide API sources.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No retrieved independent lab aggregate (Janoshik/MZ Biolabs/Finnrick) provided a quantified underdosing prevalence for cagrilintide. Janoshik lists cagrilintide as a testable analyte with a reference standard, and public test IDs exist (e.g., verify.janoshik.com/tests/40422, /57202), but the result pages were not retrievable (HTTP 403), so no prevalence figure can be cited.

• DWPE of GLP-1 Receptor Agonist Bulk Drug Substances (green list). Targets foreign-sourced GLP-1 APIs with appearance of adulteration/CGMP noncompliance; 21% of 48 evaluated GLP-1 API sites found noncompliant. Cagrilintide is an amylin/calcitonin-receptor agonist, not a GLP-1 RA, so it is not explicitly named in the alert; included here as the adjacent GLP-1 API enforcement framework cited alongside cagrilintide in FDA's GLP-1 communications.66-80
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Cagrilintide is an investigational, non-approved substance. Under the WADA 2026 Prohibited List (in force 1 January 2026), substances not approved by any governmental regulatory health authority for human therapeutic use are prohibited under S0 (Non-approved substances). Cagrilintide is not specifically named in the List but falls within the S0 category by virtue of its non-approved status.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-experimentation / anecdote dominance
• vendor-affiliated content present in results
• mechanism speculation presented as established fact
• survivorship bias toward successful appetite-suppression reports

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Long-acting amylin analogue in late-stage clinical development, studied as weekly subcutaneous co-therapy with semaglutide for obesity and type 2 diabetes. Approximately 77 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational — NDA under FDA review. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet